Canada Markets closed

Alpha Cognition Inc. (ACOGF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.4908+0.0008 (+0.17%)
At close: 03:52PM EDT
Sign in to post a message.
  • S
    Saved by grace
    Trusting in JESUS
  • D
    David
    Nothong matters except what the market makers want to do. Read their minds and you win lol
  • J
    John
    Canadian rx Company - baaaaaa
  • R
    Rudolph
    Still waiting on that data read…
  • R
    Rudolph
    Prodrug data anytime now.
  • D
    David
    Now down on the news.
    Who sold their share to make it go down?
    Lol, STONX!
  • R
    Rudolph
    So was that. Yahoo glitch or did someone put in a market order?
  • R
    Rudolph
    Been looking around here and there and there is not much chatter at all about this company! Talk about flying under the radar. Huge potential as younger investors like to make discoveries and share them.
  • R
    Rudolph
    Strong moves into a long weekend!
  • p
    partystocker
    Decent gains the past few days! Up a solid 13% and holding so far.
  • D
    Doc
    Last week, $ACOG announced they have appointed Don Kalkofen as CFO. Mr. Kalkofen has plenty of experience in the biotechnology industry and has been successful in the past serving as CFO of Protagonist Therapeutics raising around $550M for the company.

    This is great news for $ACOG as they look to increase capital and continue to grow / produce positive results. Excited to see some more updates from $ACOG this year as the company has been providing some promising results from its pre-clinical studies.

    https://ca.finance.yahoo.com/news/alpha-cognition-announces-change-cfo-130000085.html
  • K
    Kion
    This ticker is on stocktwits now
  • D
    David
    Alpha successfully defends patent!!!!!....and the stonk still gets dumped to new lows...lol, stonx
  • R
    Rudolph
    Patiently waiting for that data…
  • N
    Nan
    $ACOG.v recently announced the appointment of Don Kalkofen as Chief Financial Officer (CFO) and Michael McFadden, $ACOG ‘s CEO, to the board of directors https://ca.finance.yahoo.com/news/alpha-cognition-announces-change-cfo-130000085.html

    Kalkofen packs extensive biotechnology industry leadership experience, including a successful track record in finance, corporate development & strategic leadership. This reads as a smart move to me. Looking forward to his work at $ACOG.v

    td, $ACOG.v @ $1.01 MC $62.11 M
  • R
    Rudolph
    Not a lot of sellers; not a lot of buyers either. Big gap between the bid and ask. Waiting with high expectations.
  • p
    pennypicks
    Bet on Alpha Cognition in the Alzheimer’s space, says Raymond James

    Raymond James analyst Rahul Sarugaser is sticking with Alpha Cognition , maintaining his Outperform ”rating and target price of $3.50/share

    The company’s lead candidate, Alpha-1062, is a patented new chemical entity of galantamine being developed as a new generation acetylcholinesterase inhibitor (“AChEI”) for the treatment of Alzheimer’s disease that gives rise to minimal gastrointestinal side effects.

    Sarugaser’s latest analysis comes as a side effect of the US Centers for Medicare & Medicaid Services (CMS) publishing their national coverage analysis for the amyloid-beta mAb class, producing a coverage with evidence recommendation that restricts Alzheimer’s drug Aduhelm reimbursement to AD patients that participate in a CMS or NIH sponsored study of the drug, limiting the drug’s potential reach for maker Biogen.

    That move could have implications for Alpha Cognition, Sarugaser said.

    “By now, the CMS national coverage decision on Biogen’s amyloid-beta Alzheimer’s disease (AD) drug has hit your radar, and so the unmet need in AD remains unrequited,” Sarugaser said. “Enter Alpha Cognition that is developing ALPHA-1062: a novel, patented pro-drug of galantamine, which is a widely used, FDA-approved acetylcholinesterase inhibitor (AChEI) indicated for the treatment of patients with mild-to-moderate AD.”

    In December, Alpha Cognition released functional data from its ALPHA-1062 intranasal Traumatic Brain Injury (TBI) program, with drug administration significantly, acutely reduced the extent of the functional deficit, and improved functional recovery of TBI animals compared to untreated animals suffering a TBI.

    In addition, in four of five functional measures of recovery, the performance of ALPHA-1062 treated group was statistically indistinguishable from that of the uninjured cohort.

    “These preclinical results, combined with our clinical data demonstrating the safety and tolerability of ALPHA-1062, support its continued development for the treatment of TBI, which we believe has the potential to help millions of Americans who suffer from a TBI each year,” said Denis Kay, Chief Scientific Officer of Alpha Cognition in the company’s December 6 press release. “We are encouraged by the data thus far and confident in our progress towards developing a safe and effective treatment for this underserved population.”

    In combination with the company’s ongoing ALPHA-1062 trial, the company is looking to launch a patient tolerability trial in the second quarter, the data from which Alpha intends to use as an accelerator of adoption and as a tool to petition the FDA to change ALPHA-1062’s label. Notable changes the company hopes to make include adding mechanism of action information, clinical data included,side effect profile, and information indicating that ALPHA-1062’s starting dose is its therapeutic dose, with limited or no titration required.

    Alpha Cognition also made an executive change, bringing in Dr. Cedric O’Gorman, who has accrued more than two decades of life sciences experience in clinical development, medical affairs and medical strategy, almost exclusively in the CNS therapeutic area, and across all stages of drug development, as the company’s new Chief Medical Officer.

    “As a board-certified psychiatrist, Dr. O’Gorman’s addition to the management team provides critical support for the advancement of our clinical programs,” said Michael McFadden, CEO of Alpha Cognition in the company’s December 2 press release. “His clinical vision and proven leadership, including his extensive CNS medical and research experience, further strengthens our clinical development efforts and support the progress of our product pipeline.”

    The update prompted Sarugaser to revise some of his financial projections, though he maintains his initial projection of $17 million in revenue in the fourth quarter of 2023 after not reporting any revenue in 2021, or projecting any revenue in 2022.

    Sarugaser’s changes come in his EBITDA projections, cutting the reported loss in 2021 from $11 million to $9 million. His projections remain constant in 2022 at a $7 million loss before turning positive in 2023 at $7 million for an implied margin of 41.2 per cent.

    Looking forward, Sarugaser foresees a number of future catalysts for the company, including the release of top-line data in either April or May, a third quarter NDA filing with the U.S. Food and Drug Administration, with a goal of receiving clearance by the middle of 2023 ahead of an implied 2024 drug launch.

    “With strong tolerability data, ACOG would have firm ground to stand on while seeking superior reimbursement to galantamine and current standard-of-care AD drugs,” Sarugaser said. “Also, the better ALPHA-1062’s tolerability profile (gold standard: placebo-like), the further market penetration ACOG can expect.We believe a placebo-like tolerability profile could add 10 per cent to ACOG’s base market share; each
  • S
    StockHawk
    $ACOG.c recently announced that it received positive preclinical data from its ALPHA-0602 gene therapy program.

    $ACOG's ALPHA-0602 is designed to increase brain progranulin levels and reduce the effects of oxidative stress which is associated with ALS.

    Pre-clinical results demonstrated that ALPHA-0602 further increased progranulin levels and decreased motor neuron cell death in in vitro models along with other positive results.

    Full results here: https://finance.yahoo.com/news/alpha-cognition-announces-positive-data-130000103.html

    IMO these results are a big step forward for $ACOG and its ALPHA-0602 drug. Considering the lack of available medicines for ALS $ACOG could really blow up as it moves its drugs towards approval phases.
    VANCOUVER, British Columbia, March 29, 2022--Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) ("Alpha Cognition" (ACI), or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives
    VANCOUVER, British Columbia, March 29, 2022--Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) ("Alpha Cognition" (ACI), or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives
    finance.yahoo.com